Browsing Tag
RRMS
1 post
Contineum Therapeutics (NASDAQ: CTNM) shares slump after PIPE-307 fails to show efficacy in multiple sclerosis trial
PIPE-307 failed to meet efficacy endpoints in RRMS Phase 2, sending Contineum Therapeutics stock lower. Find out what’s next for PIPE-791 and MDD.